Cargando…
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review
RATIONALE: Sintilimab is a novel programmed cell death receptor-1 (PD-1) inhibitor approved in the treatment of classical Hodgkin's lymphoma and undergoing clinical trials for various malignancies. As a PD-1 inhibitor, sintilimab is known to cause autoimmune adverse events similar to other PD-1...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133135/ https://www.ncbi.nlm.nih.gov/pubmed/34106616 http://dx.doi.org/10.1097/MD.0000000000025795 |